Glucokinase activators (GKAs) are small-molecule agents that enhance glucose sensing by pancreatic β -cells and glucose metabolism by hepatocytes. There is strong interest in these agents as potential therapies for type 2 diabetes. Here, we report key pharmacokinetic and pharmacodynamic findings from preclinical studies of the GKA MK-0941. Incubated in vitro with recombinant human glucokinase, 1 µM MK-0941 lowered the S 0.5 of this enzyme for glucose from 6.9 to 1.4 mM and increased the maximum velocity of glucose phosphorylation by 1.5-fold.
MOL #74401

Introduction
Glucokinase activators (GKAs) are small-molecule agents that enhance the catalytic activity of glucokinase, a unique hexokinase isoform that plays a pivotal role in glucose-sensing by pancreatic β -cells and glucose metabolism by hepatocytes (Grimsby et al., 2003; Matschinsky et al., 2006) . Glucokinase activity is allosterically modifiable; binding between a GKA and glucokinase stabilizes the enzyme in a conformational state with substantially higher affinity for glucose (Kamata et al., 2004) . Most GKAs also increase the maximum velocity of glucose phosphorylation (Matschinsky, 2009) . Through these actions, GKAs markedly increase insulin release by pancreatic β -cells and uptake of glucose by hepatocytes, and do so at physiological glucose concentrations (Grimsby et al., 2003 (Grimsby et al., , 2008 Matschinsky, 2009) . There is thus considerable interest in the development of GKAs as agents that may provide a novel form of pharmacotherapy for type 2 diabetes (Matschinsky, 2009; Matschinsky and Porte, 2010;  MOL #74401
Pharmacokinetic and Pharmacodynamic Evaluation of MK-0941 in HFD Mice. After 29 weeks on a HFD, C57BL/6J HFD mice were assigned to blood glucose-matched treatment groups (9-12 per group) that received vehicle alone (1% w/v aqueous methylcellulose in 5 mL/kg body weight) or vehicle plus 1, 3, 10, or 30 mg/kg MK-0941 by gavage twice daily (at ~09:00 and ~17:00) for 14 days. The PD analysis of blood glucose levels included 9 animals from each group; 3 additional animals were included in each MK-0941-treated group for PK analysis. On Days 1, 7, and 14, blood was obtained from tail bleeds prior to dosing and at 1, 2, 4, 6, 8, and 12 h postdose. The evening dose was postponed on these days until after the last sample had been obtained. In the PD analysis, 10 µL of blood was collected and analyzed immediately with an Antsense II TM glucometer (Bayer Medical, Osaka, Japan). In the PK analysis, 50 µL of blood was collected into a heparinized capillary and centrifuged for 5 min at 12,000 rpm (at room temperature) to isolate plasma. MK-0941 concentrations were then determined as described above.
Blood Glucose in db/db Diabetic Mice Given Single Doses of MK-0941. Male db/db
and db/+ (lean) mice (9-10 weeks of age, weighing 43-45 grams) were administered single doses by gavage of either vehicle alone (0.5% methylcellulose, 10 mL/kg) or vehicle plus 3 or 10 mg/kg MK-0941. The doses were administered at ~09:00 and animals were fasted afterwards so that blood glucose levels would not be affected by possible treatment effects on feeding behavior. Using a Lifescan One Touch R Basic R glucometer (Lifescan, Inc., Milpitas, California), glucose was measured prior to dosing and at 0, 1, 2, 3, and 4 h postdose in blood from tail bleeds.
Pharmacokinetic and Pharmacodynamic Evaluation of MK-0941 in HFD/STZ Mice.
When the HFD/STZ mice were 11 weeks of age, blood samples (15 µL) were collected from the tail vein into heparinized capillaries and analyzed for content of glycated hemoglobin (HbA 1c ) using a DCA2000 or DCA2000+ HbA 1c analyzer (Bayer-Sankyo, Tokyo, Japan). At 12 weeks of This article has not been copyedited and formatted. The final version may differ from this version. age, the mice were assigned to treatment groups (10-13 per group) that received vehicle alone (5 mL/kg 1% w/v aqueous methylcellulose) or vehicle plus 10 mg/kg MK-0941 twice daily by gavage for 16 days. The PD analysis included 10 animals from each group; 3 additional animals were included in each MK-0941-treated group for PK analysis. Blood glucose was measured as described for HFD mice.
On Day 16, the mice were euthanized by isoflurane inhalation 4 h after the morning dosing. The abdomen was opened and blood was drawn from the abdominal vein into a chilled, heparinized syringe; 50 µL of this was analyzed for HbA 1c as described. The rest was centrifuged at 7,500 rpm, 4 °C for 10 min to obtain plasma. The liver was removed, weighed, and homogenized. Its lipids were extracted by the Folch method (Folch et al., 1957) and analyzed for triglycerides (TG) and total cholesterol (TC) content using the Determiner-L TG II and Determiner-L TC II enzymatic assay kits (Kyowa Medex Co., Ltd., Tokyo, Japan). Plasma free fatty acids (FFA), TG, alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), lactic acid, and 3-hydroxybutyric acid (3-HBA) levels were determined using a Hitachi autoanalyzer (Hitachi High-Technologies Corporation, Tokyo, Japan). Plasma drug concentrations were determined as described for HFD mice (see above).
Pharmacokinetic and Pharmacodynamic Evaluation of MK-0941 in Healthy Dogs.
Healthy male beagle dogs (ages 11-30 months) were assigned to treatment groups, fasted overnight, and administered by gavage single doses of vehicle alone (60% v/v aqueous polyethylene glycol 2 mL/kg), or vehicle plus 0.1, 0.3, 1, or 3 mg/kg MK-0941 (n = 3-6 per group). An oral glucose challenge (2 g/kg in 10 mL/kg saline) followed 30 min later. Prior to dosing with the study drug, prior to the glucose challenge, and at 1.0, 1.5, 2.0, 2.5, 4, 6, 8, and
Tokyo, Japan) following the procedure described in the manufacturer's protocol, but with modification of scale to accommodate analysis of smaller sample volumes. Plasma insulin levels were determined by ELISA as described for our assay of isolated rat islets (above), except that dog insulin (Morinaga Institute of Biological Science) was used as the standard.
Plasma drug concentrations were determined as described for HFD mice (see above). Food was provided to the animals beginning 3.5 h after oral glucose dosing.
In a subsequent study, healthy male beagle dogs (n = 2-4 per group) were assigned to treatment groups given daily doses of vehicle (the same as above), 1, or 10 mg/kg MK-0941 by gavage for 4 days (n = 2-4 per group). On each day prior to dosing, and at 0.5, 1, 2, 4, 6, 8, and 24 h postdose, blood samples were collected and analyzed for plasma glucose, MK-0941, and insulin content as described above. Prior to the first dose, the animals were fasted overnight. Food was provided to the animals beginning 4 h after daily doses.
Statistical Methods.
Values for EC 50 (concentrations that produced half-maximal effects), S 0.5 and V max were calculated using GraphPad Prism 3.03 and 4.00 (GraphPad Software, Inc., La Jolla, California) with a four-parameter logistic equation. In the analysis of insulin secretion by isolated islets of Langerhans, differences between outcomes in the drugtreated and vehicle-treated groups were evaluated using the Dunnett test (SAS, version 5.0; SAS Institute Inc., Cary, NC). In the analysis of blood glucose levels in db/db mice, statistical significance was tested using Student's t-test. Blood glucose concentrations in HFD mice were analyzed for significance using Tukey's multiple-comparison test (SAS, version 5.0) . Data from the dog and from HFD/STZ mice were analyzed using Dunnett's multiple comparison procedure (SAS, version 5.0). Statistical significance was defined as p < 0.05 in comparisons between actively treated and vehicle-treated groups.
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Results
Effects of MK-0941 on the Kinetics of Recombinant Human Glucokinase in Vitro.
Addition of 1 μ M MK-0941 to assays of glucokinase decreased the enzyme's S 0.5 for glucose (increased its affinity) from 6.9 ±0.47 to 1.4 ±0.20 mM and increased the V max for glucose phosphorylation by from 20.1 ±1.0 to 30.8 ±1.5 nmol/min·μg protein (Fig. 1A, B) . The EC 50 for activation of glucokinase by MK-0941 depended on glucose concentration. In 2.5 mM glucose it was 0.240 ±0.009 µM and in 10 mM glucose it was 0.065 ±0.005 µM (Fig. 1C) . Figure 2A ).
Selectivity of MK
Treatment of islets with MK-0941 increased insulin secretion and the size of the effect depended on both MK-0941 concentration and glucose concentration. In 2.5 mM glucose, the rate of insulin secretion elicited by 10 µM MK-0941 was comparable to that elicited by incubation in 16.7 mM glucose without MK-0941 ( Figure 2B ). There was also a strong effect of 1.0 µM MK-0941 on insulin secretion in 2.5 mM glucose, but 0.1 µM MK-0941 had no effect on insulin secretion at this glucose concentration. This was consistent with the fact that 0.1 µM is well below the EC 50 observed for MK-0941 in kinetic studies of glucokinase in 2.5 mM glucose glucose. These two doses lowered blood glucose similarly at 1 h postdose, suggesting that saturation of effect was approached. Over the subsequent 3 h, the reduction in glucose diminished in mice given the lower dose but was stable in mice given the higher dose.
Pharmacokinetics and Pharmacodynamics of MK-0941 in HFD/STZ Mice. Prior to treatments, HFD/STZ mice also exhibited pronounced hyperglycemia with blood glucose concentrations generally in excess of 300 mg/dL. Blood glucose levels in these mice appeared to be especially sensitive to stress caused by the gavage procedure (Tabata et al., 1998) , in that dosing with vehicle (5 mL/kg 1% w/v aqueous methylcellulose) on Day 1 was followed by further increase in blood glucose to a mean > 400 mg/dL ( Figure 5A ).
Administration of 10 mg/kg MK-0941 to HFD/STZ mice was not followed by the increase in blood glucose observed in the vehicle-treated animals. Indeed, blood glucose declined in this group from a mean (±SE) of 306±12 mg/dL prior to dosing to 269 ±28 mg/dL 4 h after dosing.
This indicates that the treatment effect more than compensated for the stress artifact. The observed differences in blood glucose between the MK-0941-treated animals and vehicletreated groups were significant at all three postdose timepoints (1, 2, and 4 h postdose). Over the 16 days of chronic dosing, this lowering of blood glucose was sustained ( Figure 5B ), although the between-group difference (treated versus vehicle controls) was not significant on Day 16.
Prior to treatments, the animals in the three HFD/STZ groups had similar levels of HbA1 c , all between 4 and 5%. At the end of 16 days of treatment HbA1 c was significantly lower in the MK-0941-treated group than in the vehicle-treated HFD/STZ controls ( Figure 5C ). In the lean control mice, mean HbA1 c was <3% throughout. In the analyses of various liver and plasma biochemical parameters (Table 2) , it was observed that total plasma cholesterol was significantly higher in the MK-0941-treated group compared with the vehicle-treated group (285 ±14 versus 215 ±20 mg/dL, respectively) and plasma 3-hydroxybutyric acid (3-HBA, a ketone body) was significantly reduced by treatment (67 ±5 mol/L compared with 120 ±17 The PK analysis in these mice showed similar levels of plasma MK-0941 on treatment Days 1 and 16 ( Figure 5A , lower plot). These plasma drug levels were also similar to those observed in the HFD mice given the 10 mg/kg MK-0941.
Pharmacokinetics and Pharmacodynamics of MK-0941 in the Dog. Single doses of 0.3, 1, and 3 mg/kg MK-0941 produced significant (p<0.05), dose-dependent reductions in plasma glucose concentrations recorded during OGTT in healthy dogs, compared with vehicle alone (Fig. 6A ). The lowest dose tested (0.1 mg/kg) did not produce a significant effect; the two highest doses (1 and 3 mg/kg) produced similar reductions in glucose, suggesting that a maximal level of response was approached. Calculated over the first 2 h following glucose challenges, area-under-the-curve (AUC) for plasma glucose was reduced, relative to vehicletreated controls, by 16 ±1.1%, 29 ±6.4%, 46 ±4.2%, and 48 ±3.0% by the doses of 0.1, 0.3, 1, and 3 mg/kg, respectively. The reductions at the doses of 0.3, 1, and 3 mg/kg were significant (p <0.05 versus vehicle). Similar levels of plasma insulin were observed across the five treatment groups (Fig. 6B) , despite the substantial reductions in plasma glucose.
In the profiles of plasma MK-0941 over time, maximal levels were observed from 1-2.5 h postdose (Fig. 6A, lower Mean body weights in the three animal groups were 11.1, 9.8, and 10.3 kg, respectively, and did not change over the four days of study.
Based on the PK data, the progression to lower levels of plasma glucose on successive days did not appear to be a consequence of drug accumulation in the plasma. The trough levels for plasma MK-0941 were 0.073 ±0.013, 0.080 ±0.022 and 0.067 ±0.011 µM on Days 2-4, respectively.
Discussion
Glucokinase is an important target of drug development because this enzyme plays pivotal roles in two key glucoregulatory functions: In the liver, glucokinase controls the first step in glucose metabolism and is thereby important in setting the rate at which glucose is converted into glycogen, and in the pancreas, glucokinase plays an essential role in glucose sensing by β -cells (Grimsby et al., 2003; Matschinsky et al., 2006) . A considerable number of GKAs have been synthesized and tested in animals out of therapeutic interest in enhancing hepatic and pancreatic glucokinase activity in patients with type 2 diabetes (Sarabu et al., 2008; 2011) .
From among these, MK-0941 and several others have entered into clinical testing.
The present data show that MK-0941 is a potent allosteric activator of human glucokinase.
It increases the affinity of glucokinase for glucose by nearly 5-fold and also increases by approximately 50% the maximum velocity (V max ) at which glucose is phosphorylated by this enzyme. These actions are highly selective for the glucokinase enzyme over its hexokinase isoforms HK I, II, and III, and this is consistent with the fact that these other hexokinases do not bear the allosteric binding site through which GKAs exert their effect on glucokinase (Kamata et al., 2004) . Analysis by x-ray crystallography has shown that MK-0941 binds to the same site as other GKAs (unpublished data).
Our in vitro data from isolated hepatocytes and islets of Langerhans suggest that MK-0941 has the potential for in vivo effects in both the liver and pancreas. In a prior study, evidence was presented for liver-selective GKA action due to hepatic conversion of an experimental compound (17c) to an active metabolite (Bebernitz et al., 2009 ).
Consistent with the interpretation of liver-selective action, treatment of diet-induced obese mice with this agent reduced plasma insulin levels during OGTT. If a GKA were to lower blood glucose primarily through action in the liver, then one would expect a compensatory reduction in insulin secretion by the pancreas. Such selective action may offer the advantage of reduced risk for hypoglycemia, although perhaps at the expense of increased risk for hepatosteatosis, hepatomegaly, and dyslipidemia.
In the present study, it was observed in the rat that MK-0941 levels were approximately 15-fold higher in the liver than in the pancreas after oral dosing. This finding suggests that MK-0941 may have a liver-preferring action, but this interpretation must be tempered by the The physiological findings in the present study suggest that MK-0941 may have a dual, but liver-preferring action site of action. During OGTT, there was no consistent change in plasma insulin levels in dogs that had been administered 0.1-3 mg/kg MK-0941, and one would expect lowering of plasma insulin if this agent were active solely in the liver. In the multiple-dose experiment in dogs, transient elevations in plasma insulin were observed each day after doses of 10 mg/kg were given. Studies of other GKAs in development have also produced evidence for dual sites of action (Grimsby et al., 2003; Futamura et al., 2006; Fyfe et al., 2007) .
Durability of antihyperglycemic efficacy is an important consideration in the development of new treatments for type 2 diabetes because this disease is both chronic and progressive (Kahn et al., 2006; Fahrbach et al., 2008) . The issue of durability is complex, however, because different processes may act over vastly different time frames to alter the efficacy (or apparent efficacy) of antihyperglycemic agents. Over the long term, it is difficult to separate consideration of a drug's durability of efficacy from the question of whether that drug alters the natural progression of type 2 diabetes; consideration over such a timeframe is beyond the scope of the present data. On the other hand, the present data do provide evidence that the action of MK-0941 is not subject to rapid loss of efficacy, such as has been observed during chronic treatments with sulfonylureas. During continuous or rapidly repeated administration, sulfonylureas may lose efficacy quickly (within hours to days) because of compensatory mechanisms that they trigger in pancreatic β -cells, mechanisms that desensitize β -cells to their insulin secretagogue action (Wåhlin-Boll et al., 1982; Rustenbeck, 2002) . In a prior study, it was observed that chronic administration of the GKA "Compound B" produced sustained glucose lowering under conditions that elicited rapid desensitization of β -cells to the glucose-lowering action of the sulfonylurea glimepiride (Ohyama et al., 2010) .
In the present study, the glucose-lowering efficacy of MK-0941 also (like Compound B)
showed stability during chronic administration. Blood glucose levels did in fact fluctuate widely within each day of dosing, but this was because MK-0941 was rapidly absorbed from the gut This article has not been copyedited and formatted. The final version may differ from this version. given to patients who are not hyperglycemic or not about to eat a meal. In the dog, blood glucose levels in the range of 80-120 mg/dL are considered normal (Bilicki et al., 2010) , and in the mouse, this range would include 100-150 mg/dL (Klueh et al., 2006) . In the present study, we observed plasma glucose levels well below these normal ranges (and glucose values in plasma are expected to differ only slightly from values measured in whole blood). It should be born in mind, however, that the dosing conditions in the present study were (by design) unlike dosing procedures that would likely be followed in a clinical setting in which MK-0941 might This article has not been copyedited and formatted. The final version may differ from this version. eventually be used as a treatment for type 2 diabetes. In our dog experiments, high doses of MK-0941 were administered to animals with normal baseline levels of plasma glucose, and in both our mouse and dog experiments, doses were given without timing to coincide with food ingestion. Given that MK-0941 is rapidly absorbed into the blood and rapidly cleared, as a clinical agent it may be particularly appropriate for use before meals as a means to control postprandial glucose excursions. 
